GT201 Injection For The Treatment Of Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-09-13
Target enrollment:
Participant gender:
Summary
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose
groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated
dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated
titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The
second and third dose groups are based on the traditional "3+3" dose-escalation principle,The
second and third dose groups are based on the traditional "3+3" dose-escalation principle,
with 3 to 6 evaluable subjects enrolled respectively.